Unraveling structural requirements of amino-pyrimidine T790M/L858R double mutant EGFR inhibitors: 2D and 3D QSAR study

被引:3
|
作者
Fatima, Shehnaz [1 ]
Agarwal, Subhash Mohan [1 ]
机构
[1] ICMR Natl Inst Canc Prevent & Res, Bioinformat Div, 1-7,Sect 39, Noida 201301, India
关键词
EGFR; double mutant inhibitor; QSAR; TMLR; CELL LUNG-CANCER; DRUG-RESISTANCE; MODEL; MUTATION; DESIGN;
D O I
10.1080/10799893.2018.1494740
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
EGFR is an important drug target in cancer. However, the ineffectiveness of first generation inhibitors due to the occurrence of a secondary mutation (T790M) results in the relapse of the disease. Identification of reversible inhibitors against T790M/L858R double mutants (TMLR) thus is a foremost requirement. In this study, various 2 D and 3 D Quantitative Structure-Activity Relationship models were built for amino-pyrimidine compounds with their known biological activity against TMLR mutants. The model developed using multiple linear regression statistical method via stepwise forward-backward variable selection technique showed the best results in terms of internal and external predictivity. The 2D-QSAR model indicated that the presence of electronegative atom, H-bond donors, moderate slogp, count of number of N atoms separated from O (T_N_O_4), 4pathClusterCount and number of S atom connected with two single bonds (SssSE-index), is required for increasing the inhibitory potential of compounds. Also, the 3D-QSAR model suggested that electronegative group at certain positions along with the presence of bulky groups is beneficial for good inhibition activity of the compounds. Thus, the QSAR models developed in the present work can be used for predicting the TMLR bioactivity of a new series of amino-pyrimidine derivatives. To the best of the author's knowledge, this is the first study which deals with the development of 2 D and 3D-QSAR models for double mutant TMLR inhibitors.
引用
收藏
页码:299 / 306
页数:8
相关论文
共 50 条
  • [41] Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC)
    Karnik, Kshipra S.
    Sarkate, Aniket P.
    Tiwari, Shailee V.
    Azad, Rajaram
    Burra, Prasad V. L. S.
    Wakte, Pravin S.
    BIOORGANIC CHEMISTRY, 2021, 107
  • [42] Synthesis and structure-activity-relationship of 3,4-Diaryl-1H-pyrrolo[2,3-b]pyridines as irreversible Inhibitors of mutant EGFR-L858R/T790M
    Guenther, Marcel
    Laux, Julian
    Laufer, Stefan
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 128 : 91 - 96
  • [43] Discovery of N-aryl-N'-pyrimidin-4-yl ureas as irreversible L858R/T790M mutant selective epidermal growth factor receptor inhibitors
    Zhou, Fusheng
    Zhang, Liang
    Jin, Yunzhou
    Liu, Wei
    Cheng, Pengfei
    He, Xiangyu
    Xie, Jing
    Shen, Sida
    Lei, Jing
    Ji, Haixia
    Hu, Yi
    Liu, Yingtao
    Cui, Yumin
    Lv, Qiang
    Lan, Jiong
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (07) : 1257 - 1261
  • [44] Double Trouble: A Case of Concurrent De Novo T790M and L858R EGFR Mutations in Treatment-Naive Advanced Non-Small-Cell Lung Cancer
    Saxena, Ashish
    Nagasaka, Misako
    Li, Zujun
    Becker, Daniel J.
    Levy, Benjamin P.
    ONCOLOGY-NEW YORK, 2014, 28 (06): : 526 - +
  • [45] In silico design of EGFRL858R/T790M/C797S inhibitors via 3D-QSAR, molecular docking, ADMET properties and molecular dynamics simulations
    Hadni, Hanine
    Elhallaouia, Menana
    HELIYON, 2022, 8 (11)
  • [46] Inhibitory effect of 1,4,5,6-tetrahydroxy-7,8-diprenylxanthone against NSCLC with L858R/T790M/C797S mutant EGFR
    Wang, Jing
    Wang, Yuna
    Zhang, Shuanggou
    Qu, Yana
    Zhang, Ruohan
    Wang, Xuanjun
    Sheng, Jun
    Sun, Peiyuan
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [47] Mechanistic Study of Potent Fluorinated EGFR Kinase Inhibitors with a Quinazoline Scaffold against L858R/T790M/C797S Resistance Mutation: Unveiling the Fluorine Substituent Cooperativity Effect on the Inhibitory Activity
    Akher, Farideh Badichi
    Farrokhzadeh, Abdolkarim
    Ravenscroft, Neil
    Kuttel, Michelle M.
    JOURNAL OF PHYSICAL CHEMISTRY B, 2020, 124 (28) : 5813 - 5824
  • [48] Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M Non-Small-Cell lung cancer (NSCLC)
    Pawara, Rahul
    Ahmad, Iqrar
    Nayak, Deepika
    Wagh, Shivani
    Wadkar, Avinash
    Ansari, Azim
    Belamkar, Sateesh
    Surana, Sanjay
    Kundu, Chanakya Nath
    Patil, Chandragauda
    Patel, Harun
    BIOORGANIC CHEMISTRY, 2021, 115
  • [49] A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties
    Yu, Lei
    Huang, Minhao
    Xu, Tianfeng
    Tong, Linjiang
    Yan, Xiao-e
    Zhang, Zhang
    Xu, Yong
    Yun, Caihong
    Xie, Hua
    Ding, Ke
    Lu, Xiaoyun
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 126 : 1107 - 1117
  • [50] Design, Synthesis and Biological Evaluation of the Quinazoline Derivatives as L858R/T790M/C797S Triple Mutant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Zhang, Mingguang
    Wang, Yunyun
    Wang, Jia
    Liu, Zhaogang
    Shi, Jingmiao
    Li, Mingxin
    Zhu, Yongqiang
    Wang, Shifa
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2020, 68 (10) : 971 - 980